Print Page  Close Window

Investor Relations
Corporate Profile

We are Zogenix.

Zogenix is committed to developing therapies that address specific clinical needs for people living with CNS and pain-related conditions who need innovative treatment alternatives to help them return to normal daily functioning.

A significant number of patients are not being effectively treated, despite the availability of current therapies. These patients deserve access to safe and effective treatments. Zogenix is committed to ensuring the safe and appropriate use of our products ... More >>

Latest PresentationsMore >>
Title
Download Documentation Zogenix January 2015 Investor Presentation
Get help downloading or viewing the above file types
Stock Quote
ZGNX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.39
Change (%) Stock is Up 0.06 (4.51%)
Volume4,830,853
Data as of 01/27/15 4:15 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
01/12/15Zogenix Provides Business Update
SAN DIEGO, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system (CNS) disorders, announced today a business update including recent company highlights, the most recent Zohydro ER prescription trends and the Company's year-end 2014 cash position. Business Update: Acquired Brabant Pharma on October 24, 2014, obtaining global rights for an or... 
Printer Friendly Version
12/03/14Zogenix to Participate in Oppenheimer 25th Annual Healthcare Conference
SAN DIEGO, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Stephen Farr, President, and Ann Rhoads, Chief Financial Officer, will present at the Oppenheimer 25th Annual Healthcare Conference in New York, NY on December 10, 2014. Event: Oppenheimer 25th Annual Healthcare Conference Date:   Wednesday, Dec... 
Printer Friendly Version
12/01/14Results of Long-Term, Open-Label Study Published in the Journal of Pain Research Demonstrate the Safety, Tolerability and Effectiveness of Zohydro(R) ER
Findings Contribute to Growing Body of Evidence Supporting Efficacy and Safety Profile SAN DIEGO, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced the publication of a long-term Phase 3 open-label study, which showed that Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, were generally safe, well-tolerated ... 
Printer Friendly Version
11/12/14Zogenix to Participate in Stifel 2014 Healthcare Conference
SAN DIEGO, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Zogenix management will present at the Stifel 2014 Healthcare Conference in New York, NY on November 18, 2014. Event: Stifel 2014 Healthcare Conference Date: Tuesday, November 18, 2014 ... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.